-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Avalo Therapeutics, Inc. to Post Q4 2022 Earnings of ($0.55) Per Share, Jefferies Financial Group Forecasts (NASDAQ:AVTX)
Avalo Therapeutics, Inc. to Post Q4 2022 Earnings of ($0.55) Per Share, Jefferies Financial Group Forecasts (NASDAQ:AVTX)
Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) – Equities researchers at Jefferies Financial Group lowered their Q4 2022 EPS estimates for Avalo Therapeutics in a research note issued to investors on Monday, November 14th. Jefferies Financial Group analyst C. Howerton now expects that the company will earn ($0.55) per share for the quarter, down from their previous estimate of $0.06. The consensus estimate for Avalo Therapeutics' current full-year earnings is ($2.66) per share. Jefferies Financial Group also issued estimates for Avalo Therapeutics' FY2023 earnings at ($0.54) EPS, FY2024 earnings at $0.02 EPS, FY2025 earnings at ($0.14) EPS and FY2026 earnings at ($0.10) EPS.
Get Avalo Therapeutics alerts:Separately, Oppenheimer cut their price objective on shares of Avalo Therapeutics to $10.00 in a report on Tuesday.
Avalo Therapeutics Stock Performance
AVTX opened at $5.41 on Thursday. Avalo Therapeutics has a twelve month low of $2.42 and a twelve month high of $27.36. The company has a debt-to-equity ratio of 5.23, a quick ratio of 1.07 and a current ratio of 1.07. The company has a 50-day moving average price of $4.94 and a 200 day moving average price of $5.21.Institutional Investors Weigh In On Avalo Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the company. Assenagon Asset Management S.A. purchased a new position in Avalo Therapeutics during the 3rd quarter worth $52,000. Leo Brokerage LLC purchased a new stake in Avalo Therapeutics during the first quarter worth about $45,000. Goldman Sachs Group Inc. raised its position in Avalo Therapeutics by 23.8% during the second quarter. Goldman Sachs Group Inc. now owns 649,653 shares of the company's stock worth $324,000 after acquiring an additional 124,769 shares during the last quarter. Renaissance Technologies LLC raised its position in Avalo Therapeutics by 819.1% during the first quarter. Renaissance Technologies LLC now owns 367,193 shares of the company's stock worth $266,000 after acquiring an additional 327,241 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in Avalo Therapeutics during the second quarter worth about $506,000.
About Avalo Therapeutics
(Get Rating)
Avalo Therapeutics, Inc, a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome.
Read More
- Get a free copy of the StockNews.com research report on Avalo Therapeutics (AVTX)
- Does ASML's November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ's Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) – Equities researchers at Jefferies Financial Group lowered their Q4 2022 EPS estimates for Avalo Therapeutics in a research note issued to investors on Monday, November 14th. Jefferies Financial Group analyst C. Howerton now expects that the company will earn ($0.55) per share for the quarter, down from their previous estimate of $0.06. The consensus estimate for Avalo Therapeutics' current full-year earnings is ($2.66) per share. Jefferies Financial Group also issued estimates for Avalo Therapeutics' FY2023 earnings at ($0.54) EPS, FY2024 earnings at $0.02 EPS, FY2025 earnings at ($0.14) EPS and FY2026 earnings at ($0.10) EPS.
阿瓦洛治療公司(納斯達克：AVTX-GET評級)--傑富瑞金融集團的股票研究人員在11月14日星期一發布給投資者的一份研究報告中下調了他們對阿瓦洛治療公司2022年第四季度每股收益的估計。傑富瑞金融集團分析師C.Howerton現在預計，該公司本季度每股收益為0.55美元，低於此前預測的0.06美元。對Avalo治療公司目前全年收益的普遍估計為每股2.66美元。傑富瑞金融集團還發布了對Avalo Treateutics 2023財年每股收益為0.54美元、2024財年每股收益為0.02美元、2025財年每股收益為0.14美元和2026財年每股收益為0.10美元的預期。
Separately, Oppenheimer cut their price objective on shares of Avalo Therapeutics to $10.00 in a report on Tuesday.
另外，奧本海默在週二的一份報告中將Avalo治療公司股票的目標價下調至10.00美元。
Avalo Therapeutics Stock Performance
Avalo治療公司股票表現
Institutional Investors Weigh In On Avalo Therapeutics
機構投資者看好Avalo治療公司
Hedge funds and other institutional investors have recently modified their holdings of the company. Assenagon Asset Management S.A. purchased a new position in Avalo Therapeutics during the 3rd quarter worth $52,000. Leo Brokerage LLC purchased a new stake in Avalo Therapeutics during the first quarter worth about $45,000. Goldman Sachs Group Inc. raised its position in Avalo Therapeutics by 23.8% during the second quarter. Goldman Sachs Group Inc. now owns 649,653 shares of the company's stock worth $324,000 after acquiring an additional 124,769 shares during the last quarter. Renaissance Technologies LLC raised its position in Avalo Therapeutics by 819.1% during the first quarter. Renaissance Technologies LLC now owns 367,193 shares of the company's stock worth $266,000 after acquiring an additional 327,241 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in Avalo Therapeutics during the second quarter worth about $506,000.
對衝基金和其他機構投資者最近調整了對該公司的持股。Assenagon Asset Management S.A.在第三季度購買了Avalo Treeutics的一個新頭寸，價值5.2萬美元。Leo Brokerage LLC在第一季度購買了Avalo治療公司的新股份，價值約4.5萬美元。第二季度，高盛公司將其在阿瓦洛治療公司的持股比例提高了23.8%。高盛股份有限公司在上個季度增持了124,769股後，目前持有649,653股該公司股票，價值324,000美元。復興技術公司在第一季度將其在阿瓦洛治療公司的地位提高了819.1%。復興科技有限責任公司在上個季度增持了327,241股後，現在擁有367,193股該公司股票，價值266,000美元。最後，Millennium Management LLC在第二季度獲得了Avalo治療公司的一個新頭寸，價值約506,000美元。
About Avalo Therapeutics
關於Avalo Treateutics
(Get Rating)
(獲取評級)
Avalo Therapeutics, Inc, a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome.
Avalo Treateutics，Inc.是一家臨牀階段的精密藥物公司，為免疫學、免疫腫瘤學和罕見遺傳病方面未得到滿足的臨牀需求的患者發現、開發和商業化靶向療法。該公司開發了AVTX-002，這是一種完全人類抗光的單抗，正在進行第二階段臨牀試驗，用於治療非嗜酸性哮喘以及炎症性腸道疾病，包括中到重度克羅恩病和潰瘍性結腸炎；以及第三階段臨牀試驗，用於治療新冠肺炎急性呼吸窘迫綜合徵。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Avalo Therapeutics (AVTX)
- Does ASML's November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ's Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
- 免費獲取StockNews.com關於Avalo治療公司(AVTX)的研究報告
- ASML的11月拉力賽有後勁嗎？
- Verra移動庫存已返回空間站
- 在盈利暴跌後，Advance Auto Parts是一筆買入嗎？
- BJ‘s批發俱樂部：當心賣方
- 馬倫汽車股票的下一個催化劑是12月23日
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《阿瓦洛治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Avalo治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧